Silver Book Fact

Cost-effectiveness of flu vaccine

Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.

Prosser L, Lavelle T, Fiore A, Bridges C, et al. Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States. PLoS ONE. 2011; 6(7). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022308

Reference

Title
Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States
Publication
PLoS ONE
Publication Date
2011
Authors
Prosser L, Lavelle T, Fiore A, Bridges C, et al
Volume & Issue
Volume 6, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…  
  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.